多发性骨髓瘤患者外周血单个核细胞c-Cbl和Cbl-b基因表达下调  

Expression down-regulation of c-Cbl and Cbl-b genes in peripheral blood mononuclear cells from multiple myeloma patients

作　　者：方苏[1] 郭翔宇[2] 冷秀秀[2] 李萡[1] 牛宇哲[1,3] 陈少华 杨力建[1] 李扬秋[1,3] 

机构地区：[1]暨南大学血液病研究所,广东广州510632 [2]第四军医大学学员七队,陕西西安710032 [3]暨南大学再生医学教育部重点实验室,广东广州510632

出　　处：《细胞与分子免疫学杂志》2013年第8期842-845,共4页Chinese Journal of Cellular and Molecular Immunology

基　　金：国家自然科学基金(30972455);中央高校基本科研业务费专项资金(11612425);广东省自然科学基金(S2012010008794);广东省科技计划(国际合作)项目(2012B050600023)

摘　　要：目的 研究多发性骨髓瘤（MM）患者外周血单个核细胞（PBMC）中c-Cbl和Cbl-b基因表达情况。方法 收集23例MM患者和22例健康人PBMC, 利用SYBR-Green 实时荧光定量PCR方法检测MM患者和健康人PBMC中c-Cbl和Cbl-b基因相对表达水平; 利用RT-PCR方法分别扩增MM患者和健康人c-Cbl基因第7-10外显子, 并对PCR产物进行序列分析。结果MM组c-Cbl表达水平（中位数0.798%）, 与健康对照组c-Cbl表达水平（中位数2.443%）相比, 显著降低（P〈0.05）; Cbl-b表达水平（中位数0.714%）与健康对照组Cbl-b表达水平（中位数2.179%）比较, 也显著降低（P〈0.05﹚。在2例MM患者中检测到c-Cbl基因第7-10外显子存在2个大小不同的片段： 483 bp和148 bp, 分别为野生型c-Cbl和删除突变的c-Cbl基因, 所有PCR产物测序后均未发现突变。结论 MM患者PBMC中c-Cbl和Cbl-b基因表达下调。Objective To investigate c-Cbl and Cbl-b gene expressions in peripheral blood mononuclear cells （PBMCs） from multiple myeloma （MM） patients. Methods SYBR Green PCR technique was used to detect c-Cbl and Cbl-b gene expressions in PBMCs from 23 MM patients and 22 healthy individuals, and RT-PCR and DNA sequence analysis were performed to analyze the mutations of 7-10 exons of c-Cbl. Results The expression of c-Cbl gene in MM patients （ median： 0.798% ） significantly decreased as compared with that in healthy controls （ median： 2.443% ） （ P 〈 0.05）. The expression of Cbl-b gene in MM patients （ median ： 0.714% ） also dropped significantly as compared with that in healthy controls （ median： 2.179% ） （ P 〈 0.05）. The 7-10 exons of c-Cbl gene had two different sizes of fragments in 2 MM patients： 483 bp and 148 bp which were wild-type and deletion mutants type of c-Cbl gene. c-Cbl gene mutations were not found in all MM patients. Conclusion The expressions of c-Cbl and Cbl-b genes in PBMCs from MM patients are down-regulated.

关 键 词：多发性骨髓瘤 C-CBL CBL-B 荧光定量PCR RT-PCR 

分 类 号：R733.3[医药卫生—肿瘤] R392.12[医药卫生—临床医学]